Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)
Sergio Amadori, Stefan Suciu, Dominik Selleslag, Roberto Stasi, Giuliana Alimena, Liliana Baila, Vittorio Rizzoli, Erika Borlenghi, Gianluca Gaidano, Domenico Magro, Giuseppe Torelli, Petra Muus, AdriVolume:
149
Year:
2010
Language:
english
Pages:
7
DOI:
10.1111/j.1365-2141.2010.08095.x
File:
PDF, 119 KB
english, 2010